国药股份(600511) - 2014 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter reached ¥2,704,890,874.74, representing a year-on-year increase of 13.74%[10] - Net profit attributable to shareholders was ¥102,018,862.05, reflecting a growth of 23.49% compared to the same period last year[10] - Basic earnings per share for the quarter were ¥0.2131, a rise of 23.54% compared to ¥0.1725 in the same period last year[10] - Total operating revenue for the current period reached ¥2,704,890,874.74, an increase of 13.7% compared to ¥2,378,139,113.92 in the previous period[25] - Net profit for the current period was ¥105,814,543.95, representing a 24.1% increase from ¥85,368,533.26 in the previous period[26] - Basic and diluted earnings per share increased to ¥0.2131 from ¥0.1725, reflecting a growth of 23.5%[26] - Operating profit for the current period was ¥119,315,349.64, a 25.3% increase from ¥95,257,081.01 in the prior period[25] - The company’s total profit for the current period was ¥129,430,784.06, an increase of 18.4% from ¥109,388,929.34 in the previous period[25] - Comprehensive income for the current period totaled ¥106,804,629.88, up 17.3% from ¥91,066,660.63 in the previous period[26] Cash Flow - Cash flow from operating activities for the quarter was ¥55,621,943.85, an increase of 50.24% year-on-year[10] - The company reported a cash inflow from operating activities of ¥3,090,320,671.98, compared to ¥2,573,476,440.20 in the previous period[32] - Cash inflow from operating activities totaled CNY 2,962,905,488.95, compared to CNY 2,441,540,588.04 in the previous period, marking an increase of 21.3%[35] - Cash outflow for operating activities was CNY 2,922,678,395.28, up from CNY 2,418,588,418.82, indicating a rise of 20.9%[35] - Cash flow from financing activities showed a net outflow of ¥19,370,252.93, compared to a net inflow of ¥12,111,063.86 in the previous period[33] - Cash inflow from financing activities was CNY 100,000,000.00, down from CNY 171,333,798.82 in the previous period, a decrease of 41.6%[38] - Cash outflow for financing activities increased to CNY 215,608,688.01 from CNY 159,222,734.96, representing a rise of 35.4%[38] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,055,358,048.85, a decrease of 0.47% compared to the end of the previous year[9] - Total current assets decreased from CNY 4,117,383,589.13 to CNY 4,039,532,473.06, a decline of approximately 1.89%[17] - Accounts receivable decreased from CNY 1,978,722,440.83 to CNY 1,882,454,540.92, a reduction of about 4.85%[17] - Inventory increased from CNY 964,104,896.10 to CNY 1,001,237,502.89, an increase of approximately 3.86%[17] - Total non-current assets increased from CNY 961,855,809.54 to CNY 1,015,825,575.79, an increase of about 5.61%[19] - Total liabilities decreased from CNY 2,883,459,395.82 to CNY 2,755,779,880.84, a decrease of approximately 4.43%[19] - Total equity increased from CNY 2,195,780,002.85 to CNY 2,299,578,168.01, an increase of about 4.73%[19] - The total assets decreased from CNY 5,079,239,398.67 to CNY 5,055,358,048.85, a decrease of about 0.47%[19] Shareholder Information - The total number of shareholders as of the reporting date was 14,983[11] - The largest shareholder, China National Pharmaceutical Group Corporation, held 44.01% of the shares, totaling 210,701,472 shares[11] Other Information - The company is actively working to resolve competition issues with its subsidiary, aiming for a comprehensive solution within five years[15] - The financial statements for the first quarter have not been audited[7] - Investment income rose to ¥27,391,480.67, up 37.5% from ¥19,859,177.97 in the previous period[28] - Operating cash flow for Q1 2014 was CNY 40,227,093.67, an increase of 75.3% compared to CNY 22,952,169.22 in the previous period[35] - The company received CNY 4,243,698.49 from investment income, a substantial increase from CNY 484,166.67 in the previous period[37] - The total cash inflow from operating activities included CNY 10,052,773.84 from tax refunds, compared to CNY 2,908,720.01 previously[35] - The company reported a cash outflow of CNY 68,373,529.36 for taxes, significantly higher than CNY 11,762,637.01 in the previous period, indicating increased tax obligations[35]